Sepracor up after allergic rhinitis data

Sepracor Inc. (NASDAQ:SEPR) gained $0.74 to $14.09 on Monday after preliminary data showed Omnaris HFA ciclesonide met the primary endpoint of significantly reducing the 24-hour reflective total nasal symptom score (TNSS) vs. placebo in a Phase III trial to treat seasonal allergic rhinitis (p<0.0001). The double-blind trial enrolled 707 adult and adolescent patients at least 13 years old. An NDA submission for the aerosol nasal formulation of ciclesonide is expected in late 2010 or early 2011. ...